Pharmacotherapeutics of Malaria

 Pharmacotherapeutics of Malaria

1. Definition

• Malaria is an infectious disease caused by Plasmodium species and transmitted mainly through the bite of an infected female Anopheles mosquito.
• The important human malaria parasites are:
• Plasmodium falciparum
• Plasmodium vivax
• Plasmodium malariae
• Plasmodium ovale
• Plasmodium knowlesi
• P. falciparum is particularly important because it can cause severe and life-threatening malaria.

2. Causative Organisms

Plasmodium falciparum

• Most dangerous species.
• Common cause of severe malaria.
• May cause cerebral malaria, severe anemia, renal failure, and shock.

Plasmodium vivax

• Common cause of malaria in many regions.
• Forms dormant hypnozoites in the liver.
• Can cause relapse.

Plasmodium ovale

• Also forms liver hypnozoites.
• Can cause relapse.

Plasmodium malariae

• Usually produces a chronic infection.
• Does not form hypnozoites.

Plasmodium knowlesi

• Can cause rapidly progressive malaria.
• May produce severe disease.

3. Mode of Transmission

• Mainly transmitted through the bite of an infected female Anopheles mosquito.
• Rare transmission can occur through:
• Blood transfusion.
• Contaminated needles.
• Organ transplantation.
• Congenital transmission.

4. Life Cycle and Pathophysiology

• An infected mosquito injects sporozoites into the human bloodstream.
• Sporozoites travel to the liver.
• They enter hepatocytes and undergo development.
• The liver stage produces merozoites.
• Merozoites enter red blood cells.
• They develop through:
• Ring stage.
• Trophozoite stage.
• Schizont stage.
• Red blood cells rupture and release new merozoites.
• Repeated RBC destruction produces:
• Fever.
• Chills.
• Sweating.
• Anemia.
• Some parasites develop into gametocytes, which are taken up by mosquitoes during a blood meal.
• The sexual stage occurs inside the mosquito.

Important point

P. vivax and P. ovale → hypnozoites in liver → relapse.

5. Clinical Manifestations

Typical symptoms

• Fever.
• Chills.
• Sweating.
• Headache.
• Muscle and joint pain.
• Weakness.
• Fatigue.
• Nausea and vomiting.
• Abdominal discomfort.

Severe malaria

Especially associated with P. falciparum.

Features may include:

• Altered consciousness.
• Cerebral malaria.
• Severe anemia.
• Hypoglycemia.
• Acute kidney injury.
• Respiratory distress.
• Metabolic acidosis.
• Jaundice.
• Shock.
• Abnormal bleeding.
• Multiorgan failure.

6. Diagnosis

Important diagnostic methods include:

• Peripheral blood smear.
• Thick smear → useful for detecting parasites.
• Thin smear → useful for species identification and parasitemia.
• Rapid diagnostic tests (RDTs).
• Molecular tests such as PCR in selected settings.
• CBC to assess anemia and platelet count.
• Blood glucose in suspected severe malaria.
• Renal and liver function tests in severe disease.

Important point

A suspected case of malaria should be diagnosed promptly and treated without unnecessary delay, particularly when severe malaria is suspected.

7. Goals of Pharmacotherapy

The main goals are:

• Rapidly eliminate malaria parasites.
• Cure the infection.
• Prevent progression to severe malaria.
• Prevent complications.
• Prevent relapse in P. vivax and P. ovale.
• Reduce transmission.
• Prevent treatment failure and drug resistance.

8. Classification of Antimalarial Drugs

Major antimalarial drugs include:

Artemisinin derivatives

• Artesunate.
• Artemether.
• Dihydroartemisinin.

Artemisinin-based combination therapies

• Artemether + lumefantrine.
• Dihydroartemisinin + piperaquine.
• Artesunate + amodiaquine.
• Artesunate + mefloquine.

4-aminoquinolines

• Chloroquine.

Quinoline-related drugs

• Quinine.
• Mefloquine.

Antifolate drugs

• Sulfadoxine + pyrimethamine.
• Pyrimethamine.

8-aminoquinolines

• Primaquine.
• Tafenoquine.

Other drugs

• Atovaquone + proguanil.

9. Treatment of Uncomplicated P. falciparum Malaria

Artemisinin-Based Combination Therapy (ACT)

• ACT is the major treatment approach for uncomplicated P. falciparum malaria.
• Common examples include:
• Artemether + lumefantrine
• Dihydroartemisinin + piperaquine
• Artesunate + amodiaquine
• Artesunate + mefloquine

Why combination therapy?

• Artemisinin rapidly reduces parasite numbers.
• The partner drug eliminates remaining parasites.
• Combination therapy reduces the risk of treatment failure and development of resistance.

10. Artemisinin Derivatives

Artesunate

Mechanism of action

• Artemisinin compounds contain an endoperoxide bridge.
• In the presence of parasite-associated iron/heme, reactive intermediates are generated.
• These damage essential parasite proteins and cellular components.
• Parasites are rapidly cleared from the blood.

Uses

• Severe malaria.
• Used as part of ACT for uncomplicated malaria.

Important point

IV artesunate is preferred for severe malaria.

11. Artemether + Lumefantrine

Mechanism

• Artemether rapidly decreases parasite biomass.
• Lumefantrine provides longer-lasting antimalarial activity.
• Together they produce effective parasite clearance.

Uses

• Uncomplicated P. falciparum malaria in areas where this regimen is recommended.

Adverse effects

• Headache.
• Dizziness.
• Nausea.
• Abdominal discomfort.
• Potential QT prolongation.

Counseling point

• Lumefantrine absorption is improved when taken with food containing some fat.

12. Treatment of Severe Malaria

Severe malaria is a medical emergency.

Preferred treatment

IV artesunate

→ Continue parenteral treatment until the patient can tolerate oral therapy

→ Complete an appropriate full oral antimalarial regimen, usually an ACT.

Supportive management

• Maintain airway and breathing.
• Correct hypoglycemia.
• Manage severe anemia.
• Treat seizures.
• Correct fluid and electrolyte abnormalities carefully.
• Manage acute kidney injury.
• Treat shock.
• Monitor parasitemia.
• Monitor vital signs and organ function.

Important point

Do not delay antimalarial therapy when severe malaria is strongly suspected.

13. Chloroquine

Mechanism

• Chloroquine accumulates inside the parasite's food vacuole.
• It interferes with detoxification of toxic heme produced during hemoglobin digestion.
• Toxic heme accumulates and damages the parasite.

Uses

• Effective against chloroquine-sensitive P. vivax, P. ovale, and P. malariae.
• P. falciparum is widely resistant to chloroquine in many regions.

Adverse effects

• Nausea.
• Headache.
• Pruritus.
• Visual toxicity with prolonged use.
• Rare cardiac toxicity.

Important point

Chloroquine is used only when the parasite is known or expected to be susceptible.

14. Treatment of P. vivax and P. ovale

Treatment has two important components:

A. Blood-stage treatment

• Chloroquine may be used where the parasite remains chloroquine-sensitive.
• In areas with chloroquine-resistant P. vivax, an appropriate ACT or another recommended regimen is used.

B. Radical cure

• Primaquine or tafenoquine is used to eliminate dormant liver hypnozoites.
• This prevents future relapses.

Very important

Before giving primaquine or tafenoquine:

Check G6PD status.

These drugs can cause hemolytic anemia in people with significant G6PD deficiency.

15. Primaquine

Drug class

• 8-aminoquinoline.

Mechanism

• Active against liver-stage parasites, particularly hypnozoites.
• Helps prevent relapse of P. vivax and P. ovale.

Uses

• Radical cure of P. vivax.
• Radical cure of P. ovale.
• Gametocidal activity against P. falciparum.

Major adverse effect

• Hemolytic anemia, especially in patients with G6PD deficiency.

Important precaution

G6PD testing is required before treatment.

16. Tafenoquine

• Long-acting 8-aminoquinoline.
• Used for radical cure of P. vivax in appropriate patients.
• Eliminates dormant liver-stage parasites.
• Can cause hemolysis in G6PD deficiency.

Important point

G6PD testing is essential before tafenoquine.

17. Quinine

Mechanism

• Interferes with parasite heme detoxification.
• Damages the parasite during the blood stage.

Uses

• Alternative treatment in selected circumstances.
• Its role has decreased because safer and more effective regimens are available.

Adverse effects

Cinchonism:

• Tinnitus.
• Headache.
• Dizziness.
• Nausea.
• Visual disturbances.

Other important adverse effects:

• Hypoglycemia.
• QT prolongation.
• Hemolysis in susceptible patients.
• Thrombocytopenia.

18. Mefloquine

Uses

• Used in certain ACT regimens.
• Also has a role in malaria prevention in selected settings.

Adverse effects

• Nausea.
• Dizziness.
• Sleep disturbances.
• Abnormal dreams.
• Neuropsychiatric reactions.

Important precaution

• Avoid or use cautiously in patients with certain psychiatric or seizure disorders.

19. Atovaquone + Proguanil

Mechanism

• Atovaquone interferes with parasite mitochondrial electron transport.
• Proguanil inhibits folate-related pathways and enhances atovaquone activity.

Uses

• Treatment and prevention of malaria in appropriate settings.

Adverse effects

• Nausea.
• Abdominal pain.
• Headache.
• Diarrhea.

20. Antifolate Drugs

Sulfadoxine + Pyrimethamine

• Inhibits sequential steps in folate metabolism.
• Resistance limits its use for routine treatment of malaria in many regions.
• It has important roles in malaria prevention during pregnancy in specific endemic settings, according to public-health guidelines.

21. Prevention of Malaria

Prevention involves both chemoprophylaxis and vector control.

Personal protection

• Use insecticide-treated bed nets.
• Use mosquito repellents.
• Wear protective clothing.
• Use window and door screens.
• Avoid mosquito exposure, particularly during peak biting times.

Vector control

• Indoor residual spraying.
• Reduction of mosquito breeding sites.
• Community-level mosquito-control programs.

Chemoprophylaxis

Depending on destination, resistance patterns, and patient factors:

• Atovaquone + proguanil.
• Doxycycline.
• Mefloquine.
• Other region-specific options.

22. Malaria in Pregnancy

• Malaria during pregnancy can cause serious maternal and fetal complications.
• Treatment should follow current national/WHO recommendations and depend on:
• Species.
• Severity.
• Trimester.
• Local resistance patterns.
• Severe malaria requires urgent parenteral therapy.
• Drug selection must consider pregnancy safety.

23. Drug Resistance

Antimalarial resistance is a major public-health problem.

Resistance may develop due to:

• Inappropriate drug selection.
• Incorrect dosing.
• Poor adherence.
• Monotherapy.
• Incomplete treatment.

Prevention

• Use recommended combination therapies.
• Ensure correct dose and duration.
• Promote adherence.
• Monitor treatment response.
• Follow national malaria treatment guidelines.

24. Important Adverse Effects to Remember

Chloroquine

• Pruritus.
• Gastrointestinal effects.
• Retinal toxicity with prolonged exposure.

Quinine

• Cinchonism.
• Hypoglycemia.
• QT prolongation.

Primaquine

• Hemolytic anemia in G6PD deficiency.

Mefloquine

• Neuropsychiatric effects.

Artemisinin combinations

• Headache.
• Nausea.
• Dizziness.
• Potential QT effects depending on the combination.

Amph?

• Not an antimalarial—do not confuse amphotericin B with antimalarial drugs.

25. Simple Treatment Flowchart

Suspected malaria

⬇️

Confirm diagnosis + identify species/severity

⬇️

Uncomplicated malaria

P. falciparum

→ Appropriate ACT

⬇️

Complete full treatment course

P. vivax / P. ovale

→ Treat blood stage

→ PLUS primaquine/tafenoquine for radical cure

→ Check G6PD status first

Severe malaria

→ IV artesunate immediately

→ Supportive management

→ Once clinically improved → complete oral antimalarial regimen

26. Key Exam Points

• Most dangerous species: P. falciparum
• Relapse: P. vivax and P. ovale
• Dormant liver stage: Hypnozoite
• Drug for hypnozoites: Primaquine / Tafenoquine
• Before primaquine/tafenoquine: Check G6PD
• Severe malaria: IV artesunate
• Uncomplicated falciparum: ACT
• Classic chloroquine mechanism: Inhibits heme detoxification
• Major quinine toxicity: Cinchonism + hypoglycemia
• Major primaquine toxicity: Hemolysis in G6PD deficiency
• Main vector: Female Anopheles mosquito

Summary

Malaria is a parasitic disease caused by Plasmodium species and transmitted mainly by the female Anopheles mosquito. P. falciparum is the major cause of severe and potentially fatal malaria, while P. vivax and P. ovale can form dormant liver hypnozoites responsible for relapse. Pharmacotherapy depends on the parasite species and severity. Artemisinin-based combination therapy (ACT) is central to treatment of uncomplicated P. falciparum malaria, whereas IV artesunate is the preferred treatment for severe malaria. P. vivax and P. ovale require treatment of both blood-stage parasites and, when appropriate, dormant liver stages with primaquine or tafenoquine after G6PD assessment. Prevention includes insecticide-treated bed nets, mosquito control, personal protection, and appropriate chemoprophylaxis. Rational drug selection, adherence, early diagnosis, and prevention of drug resistance are essential for effective malaria control.

 

END OF THE DOCUMENTS